UA91497C2 - Use of peptides derived from the a alpha or b beta chain of human fibrinogen for the treatment of shock - Google Patents
Use of peptides derived from the a alpha or b beta chain of human fibrinogen for the treatment of shockInfo
- Publication number
- UA91497C2 UA91497C2 UAA200604047A UAA200604047A UA91497C2 UA 91497 C2 UA91497 C2 UA 91497C2 UA A200604047 A UAA200604047 A UA A200604047A UA A200604047 A UAA200604047 A UA A200604047A UA 91497 C2 UA91497 C2 UA 91497C2
- Authority
- UA
- Ukraine
- Prior art keywords
- moiety
- denotes
- shock
- peptide
- alpha
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention relates to the use of a peptide of general formula (II),whereinR1 and R2, being equal or different, denote hydrogen, a saturated or unsaturated hydrocarbon moiety comprising from 1 to 10, in particular from 1 to 3, carbon atoms,Z1 denotes a histidine or proline moiety,Arg denotes an arginine moiety,Z3 denotes a proline or valine moiety,Z4 denotes a leucine or valine moiety,Z5 is a peptide moiety derived from the Bß-chain of the fibrin,said peptide possessing the biological property of matching the inducible VE-cadherin binding motive on the Bß-chain (i.e. Bß) of human fibrin, for the production of a pharmaceutical preparation used to treat shock.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0108704A AT414097B (en) | 2004-06-25 | 2004-06-25 | Treatment of shock, e.g. due to bacterial toxins or hemorrhagic shock associated with viral infections, comprises using peptides matching the inducible VE-cadherin binding moiety of human fibrin Bbeta-chain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA91497C2 true UA91497C2 (en) | 2010-08-10 |
Family
ID=35508712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200604047A UA91497C2 (en) | 2004-06-25 | 2005-06-24 | Use of peptides derived from the a alpha or b beta chain of human fibrinogen for the treatment of shock |
Country Status (4)
| Country | Link |
|---|---|
| CN (1) | CN1842344A (en) |
| AT (1) | AT414097B (en) |
| UA (1) | UA91497C2 (en) |
| ZA (1) | ZA200602053B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT502987A1 (en) | 2005-12-23 | 2007-07-15 | Fibrex Medical Res & Dev Gmbh | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF HEMORRHAGIC SHOCK AND ITS AFFILIATES |
| CN101937002A (en) * | 2010-07-23 | 2011-01-05 | 合肥天一生物技术研究所 | Hemoglobin visual inspection reagent |
| EP2844270A4 (en) * | 2012-03-15 | 2016-01-27 | Univ New York State Res Found | Combination therapies including inhibitors of the extracellular domain of e-cadherin |
-
2004
- 2004-06-25 AT AT0108704A patent/AT414097B/en not_active IP Right Cessation
-
2005
- 2005-06-24 ZA ZA200602053A patent/ZA200602053B/en unknown
- 2005-06-24 UA UAA200604047A patent/UA91497C2/en unknown
- 2005-06-24 CN CNA2005800009931A patent/CN1842344A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200602053B (en) | 2007-06-27 |
| AT414097B (en) | 2006-09-15 |
| CN1842344A (en) | 2006-10-04 |
| ATA10872004A (en) | 2005-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL173969A0 (en) | Use of peptides derived from the a alpha or b beta chain of human of human fibrinogen for the treatment of shock | |
| WO2006113681A3 (en) | Plant-derived elastin binding protein ligands and methods of using the same | |
| DK0750506T3 (en) | Widespread, antimicrobial compounds and methods for their use | |
| AR062065A1 (en) | HUMANIZED ANTIBODY | |
| NZ593815A (en) | Tissue factor pathway inhibitor (tfpi) inhibitors and methods of use | |
| CY1111225T1 (en) | NEW Peptides As NS3-Serine Protease Inhibitors Inhibit C | |
| WO2005116051A3 (en) | Tumor-associated peptides that bind to mhc-molecules | |
| AU2003264419A1 (en) | Kdr peptides and vaccines containing the same | |
| DK2231860T3 (en) | Polypeptide derived protein A and capable of binding PDGF | |
| WO2009004315A8 (en) | Isolated peptides and uses thereof | |
| WO2005097828A3 (en) | Peptides of cav2.2 that inhibit pain | |
| EP1071443A4 (en) | Isolated peptides corresponding to amino acid sequences of ny-eso-1, wherein bind to mhc class i and mhc class ii molecules, and uses thereof | |
| UA91497C2 (en) | Use of peptides derived from the a alpha or b beta chain of human fibrinogen for the treatment of shock | |
| YU53803A (en) | Peptides and/or proteins and use thereof for the production of a therapeutic and/or prophylactic medicament | |
| WO2007013358A3 (en) | Vivit polypeptides, therapeutic agent comprising the same, and method of screening for anti-cancer agent | |
| MXPA05008080A (en) | Peptide inhibitors of toxins derived from ll-37. | |
| ATE538806T1 (en) | PEPTIDES SPECIFICALLY SITE IN CARDIAC VESSELS AND RELATED CONJUGATES AND METHODS | |
| DE602006017806D1 (en) | TREATMENT OF NEURODE GENERATION | |
| AR026068A1 (en) | MODIFIED AND PEPTIDOMIMETIC PEPTIDES FOR USE IN IMMUNOTHERAPY. | |
| PL1625152T3 (en) | Peptides modulating the activity of the engrailed transcription factor | |
| EP1724346A3 (en) | Peptides binding to the Lck-SH3 and to the Hck-SH3 domain | |
| IL151211A0 (en) | Compositions useful for regulating parkin gene activity | |
| HK1083850A1 (en) | Peptides binding the phosphatase 2a protein and polynucleotides encoding same | |
| GB9901710D0 (en) | Peptide inhibitors | |
| WO2024076689A3 (en) | Size-discriminating nucleic acid-binding complexes and methods of use thereof |